|Source||Humanized (from mouse)|
|(what is this?)|
Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer. It selectively binds to carcinoembryonic cell adhesion molecule 5. 
Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis.
This drug was developed by Immunomedics, Inc.
- "International Nonproprietary Names for Pharmaceutical Substances (INN): Labetuzumab" (PDF). WHO Drug Information. 16 (1): 95. 2002.
- "labetuzumab-SN-38 immunoconjugate IMMU-130". National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. Department of Health and Human Services.